Expanded access and new panels put Quest Diagnostics’ QHerit carrier screen in focus

Quest Diagnostics is pushing its QHerit expanded carrier screening panel further into routine preconception and prenatal care, adding access through more providers while highlighting its coverage of more than 280 genetic conditions and detailed residual-risk reporting for parents-to-be.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 1:30 PM ET. Details in the imprint.

Quest Diagnostics’ QHerit expanded carrier screening panel is steadily moving from a specialist tool into a mainstream option in OB/GYN and fertility practices, as the company leans on more than 20 years of genetics experience and a broad provider network to grow adoption among parents planning a pregnancy.

The QHerit portfolio currently spans multiple preconception and prenatal carrier screen options, including a panel that analyzes variants in more than 280 genes linked to inherited conditions such as cystic fibrosis, spinal muscular atrophy and hemoglobinopathies, with reports that summarize both carrier status and residual risk for future children. Quest’s clinical education materials on QHerit describe the test as designed for diverse ethnic backgrounds and compatible with standard practice guidelines.

What QHerit aims to deliver in everyday practice

At its core, QHerit is a blood-based laboratory test: clinicians order the panel, collect a sample via routine venipuncture and ship it to a Quest high-complexity genetics laboratory, where next-generation sequencing and targeted analysis identify pathogenic or likely pathogenic variants in selected genes associated with autosomal recessive or X-linked disorders. The company positions the test primarily for individuals or couples who are pregnant or planning a pregnancy, including those using assisted reproductive technologies, and emphasizes that testing one partner first is usually sufficient, with reflex testing of the other partner if necessary.

Quest highlights several practical features for clinicians, including concise result summaries that categorize findings as increased risk, reduced risk or population risk, as well as detailed variant descriptions and suggested next steps that can be incorporated into counseling or referrals to genetics professionals. The test is aligned with current professional guidelines that recommend carrier screening for conditions like cystic fibrosis and spinal muscular atrophy for all women considering pregnancy, but QHerit’s extended panels go further by bundling dozens to hundreds of additional conditions into a single orderable test code.

In terms of coverage, QHerit panels track key categories of inherited disease that are frequently requested in preconception counseling, such as cystic fibrosis transmembrane conductance regulator (CFTR) variants, SMN1 gene variants linked to spinal muscular atrophy, hemoglobinopathies including sickle cell disease and thalassemias, and a broad set of metabolic and neurologic conditions that follow autosomal recessive inheritance patterns. For many of these conditions, Quest reports that the panel includes variants relevant across multiple ancestral backgrounds rather than focusing solely on historically high-risk populations.

Because carrier screening is often bundled into standard prenatal workflows, Quest also stresses operational aspects: the QHerit test is available through its national network of patient service centers and in-office phlebotomy programs, with electronic ordering and result delivery integrated into many electronic health record systems commonly used by OB/GYN practices. The company notes that it offers optional pre- and post-test genetic counseling support via third-party partners or internal genetics staff for complex cases, though counseling requirements may vary by practice and payer.

For payers and patients, cost is an important variable. Quest states in its payer-facing materials that QHerit is covered by a number of commercial health plans, Medicare Advantage policies and Medicaid programs when ordered in line with plan-specific medical policies, while self-pay pricing and financial assistance programs are available for uninsured or underinsured patients. Aetna, for example, lists expanded carrier screening, including panels covering 200 or more conditions, as potentially medically necessary under certain risk-based criteria in its clinical policy bulletins. Aetna’s clinical policy on genetic testing and carrier screening references multi-gene panels for preconception and prenatal use.

From a clinical perspective, the move toward broader carrier screening like QHerit reflects the growing consensus that ethnicity-based testing alone misses significant numbers of carriers in increasingly diverse populations. By offering a standardized, panel-based test that can be applied across demographics, Quest aims to simplify ordering for clinicians and reduce inequities in access to information about inherited risks, though the company and professional societies also caution that negative results do not eliminate the possibility of having an affected child because not all pathogenic variants are detectable.

For fertility clinics and reproductive endocrinologists, QHerit’s extended panels can be integrated into pre-IVF workups so that carrier status informs embryo selection or donor choices when applicable. These providers often require both partners in a couple, and sometimes donors, to undergo carrier screening for a predefined list of genes, and a ready-made panel with standardized reporting can streamline this process. Quest’s Boston-area and Marlborough genetics laboratories, which the company references in recruitment materials for senior scientists, are among the facilities supporting its growing menu of molecular and next-generation sequencing-based assays. A Quest job posting for an NGS-focused senior scientist highlights its investment in complex genetic testing infrastructure.

Quest Diagnostics positions QHerit within a broader women’s health portfolio that also includes noninvasive prenatal testing, maternal serum screening and infectious disease panels, giving obstetric providers the option to consolidate much of their laboratory work with a single national lab partner. For Quest, expanded carrier screening adds a higher-value, specialized genetics layer on top of routine blood work, which can support revenue growth per patient encounter while also bolstering relationships with health systems that want consistent lab workflows across primary care, obstetrics and fertility.

From a market standpoint, expanded carrier screening remains a competitive space, with other large reference labs and specialized genetics companies offering their own multi-gene panels and digital tools for preconception counseling. QHerit competes on breadth of gene coverage, integration with existing Quest ordering channels and the company’s scale in the United States, which can make logistics and billing simpler for practices already using Quest for routine tests. How aggressively individual payers reimburse for large panels versus targeted screens continues to shape which QHerit configurations practices choose in day-to-day care.

For Quest Diagnostics, high-complexity genetics services like QHerit complement its core routine testing business and support its strategic framing as a provider of insights rather than just lab numbers. The company has emphasized genetics and advanced diagnostics as a growth vector in investor presentations, although it does not typically break out revenue from individual test brands. Shares of Quest Diagnostics (US74834L1008) traded on the NYSE at $140.87 on 06/14/2026, according to end-of-day data from the exchange.

QHerit carrier screening in brief: key data points

• Product: QHerit expanded carrier screening panel
• Manufacturer: Quest Diagnostics Incorporated
• Category: Flagship/Bestseller genetic test
• Launch date: Initial launch mid-2010s; expanded panels added subsequently
• MSRP / Price: Varies by insurance coverage and panel size; self-pay options available
• Availability: Ordered through clinicians across the US with sample collection at Quest patient service centers and participating practices
• Target audience: Individuals and couples who are pregnant or planning pregnancy, including fertility clinic patients
• Key differentiator / USP: Broad panel covering more than 280 genes with standardized reporting and national logistical support

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.